Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.9K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.3K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.3K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

376
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
376
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

12.8K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12.8K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

371
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
371
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visualization of liquid-liquid phase transitions using a tiny G-quadruplex binding protein.

bioRxiv : the preprint server for biology·2024
Same author

Risk-based approach to setting sterile filtration microbial bioburden limits - Focus on biotech-derived products.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2023
Same author

Modeling immunogenecity data to establish screening bioassays cut point.

Pharmaceutical statistics·2023
Same author

RNA-seq data science: From raw data to effective interpretation.

Frontiers in genetics·2023
Same author

A comparison of statistical methods for animal oncology studies.

Pharmaceutical statistics·2022
Same author

A Bayesian Statistical Approach to Continuous Qualification of a Bioassay.

PDA journal of pharmaceutical science and technology·2020

Related Experiment Video

Updated: Apr 12, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K

Testing drug additivity based on monotherapies.

Harry Yang1, Steven J Novick2, Wei Zhao1

  • 1MedImmune LLC, One MedImmune Way, Gaithersburg, MD, USA.

Pharmaceutical Statistics
|May 13, 2015
PubMed
Summary
This summary is machine-generated.

Testing drug additivity requires demonstrating parallelism between dose-response curves. A novel Bayesian approach directly tests constant relative potency, overcoming limitations of traditional significance tests for combination studies.

Keywords:
BayesianLoewe additivitydose-response curveparallelism testingprior distribution

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.7K

Related Experiment Videos

Last Updated: Apr 12, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.7K

Area of Science:

  • Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Loewe additivity defines drug additivity by constant relative potency, geometrically represented as parallel dose-response curves.
  • Current parallelism testing relies on significance tests of dose-response curve parameters, which can be flawed with increased sample size or assay precision.
  • Parameter similarity does not guarantee response curve similarity, potentially leading to inaccurate conclusions about drug additivity.

Purpose of the Study:

  • To introduce a Bayesian approach for directly testing constant relative potency between two drugs.
  • To address the limitations of traditional p-value-based methods for assessing drug additivity and parallelism.
  • To provide a robust method for aiding go/no-go decisions in two-drug combination studies.

Main Methods:

  • Developed a Bayesian statistical framework to directly assess the hypothesis of constant relative potency.
  • Applied the method to simulated data to evaluate its performance.
  • Validated the approach using a real-world drug combination case study.

Main Results:

  • The proposed Bayesian method directly tests the core assumption of constant relative potency for additivity.
  • Demonstrated the method's utility in overcoming the statistical pitfalls of traditional significance testing.
  • Provided a more reliable assessment of dose-response curve parallelism and drug additivity.

Conclusions:

  • The Bayesian approach offers a direct and reliable method for testing constant relative potency, crucial for establishing drug additivity.
  • This method enhances decision-making in drug combination development by providing a more accurate assessment of drug interactions.
  • The study highlights the importance of directly testing the hypothesis of interest rather than relying on indirect parameter comparisons.